ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2016, Vol. 30 ›› Issue (4): 10-14.doi: 10.6040/j.issn.1673-3770.0.2016.280
张革化,李文婷
ZHANG Gehua, LI Wenting
中图分类号:
| [1] Zhang Y, Zhang L. Prevalence of allergic rhinitis in china[J]. Allergy Asthma Immunol Res, 2014, 6(2):105-113. [2] Zuberbier T, Lotvall J, Simoens S, et al. Economic burden of inadequate management of allergic diseases in the European Union: a GA(2)LEN review[J]. Allergy, 2014, 69(10):1275-1279. [3] Bousquet J, Khaltaev N, Cruz A A, et al. Allergic rhinitis and its impact on asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA2LEN and AllerGen)[J]. Allergy, 2008, 63(Suppl 86):8-160. [4] Brozek J L, Bousquet J, Baena-Cagnani C E, et al. Allergic rhinitis and its impact on asthma(ARIA)guidelines: 2010 revision[J]. J Allergy Clin Immunol, 2010, 126(3):466-476. [5] Okubo K, Kurono Y, Fujieda S, et al. Japanese Guideline for Allergic Rhinitis 2014[J]. Allergology International, 2014, 63(3):357-375. [6] Seidman M D, Gurgel R K, Lin S Y, et al. Clinical practice guideline: allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(Suppl 1):S1-S43. [7] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组,中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志,2016, 51(1):6-24. [8] Anolik R. Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008, 100(3):264-271. [9] Rodrigo G J, Neffen H. Efficacy of fluticasone furoate nasal spray vs. placebo for the treatment of ocular and nasal symptoms of allergic rhinitis: a systematic review[J]. Clin Exp Allergy, 2011, 41(2):160-170. [10] Penagos M, Compalati E, Tarantini F, et al. Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials[J]. Allergy, 2008, 63(10):1280-1291. [11] Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost[J]. Am J Rhinol, 2007, 21(1):70-79. [12] Bielory L, Chun Y, Bielory B P, et al. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis[J]. Allergy, 2011, 66(5):686-693. [13] Ratner P H, Meltzer E O, Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(5):651-657. [14] Tripathy I, Levy A, Ratner P, et al. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis[J]. Pediatr Allergy Immunol, 2009, 20(3):287-294. [15] Schenkel E J, Skoner D P, Bronsky E A, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray[J]. Pediatrics, 2000, 105(2):E22. [16] Karaki M, Akiyama K, Mori N. Efficacy of intranasal steroid spray(mometasone furoate)on treatment of patients with seasonal allergic rhinitis: comparison with oral corticosteroids[J]. Auris Nasus Larynx, 2013, 40(3):277-281. [17] Wheatley L M, Togias A. Clinical practice. Allergic rhinitis[J]. N Engl J Med, 2015, 372(5):456-463. [18] Horak F, Zieglmayer U P, Zieglmayer R, et al. Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy[J]. Curr Med Res Opin, 2006, 22(1):151-157. [19] Kaliner M A, Berger W E, Ratner P H, et al. The efficacy of intranasal antihistamines in the treatment of allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2011,106(Suppl 2):S6-S11. [20] Benninger M, Farrar J R, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class[J]. Ann Allergy Asthma Immunol, 2010, 104(1):13-29. [21] Meltzer E O, Bernstein D I, Prenner B M, et al. Mometasone furoate nasal spray plus oxymetazoline nasal spray: short-term efficacy and safety in seasonal allergic rhinitis[J]. Am J Rhinol Allergy, 2013, 27(2):102-108. [22] Cruz A A, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA2LEN[J]. Allergy, 2007, 62(Suppl 84):1-41. [23] Bousquet J, Schünemann H J, Samolinski B, et al. Allergic rhinitis and its impact on asthma(ARIA): achievements in 10 years and future needs[J]. J Allergy Clin Immunol, 2012, 130(5):1049-1062. [24] Lohia S, Schlosser R J, Soler Z M. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis[J]. Allergy, 2013, 68(5):569-579. [25] Seidman M D, Gurgel R K, Lin S Y, et al. Clinical practice guideline: allergic rhinitis executive summary[J]. Otolaryngol Head Neck Surg, 2015, 152(2):197-206. [26] Ratner P H, Andrews C, Martin B, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol in patients with seasonal allergic rhinitis from mountain cedar pollen[J]. Allergy Asthma Proc, 2012, 33(1):27-35. [27] Leach C L, Kuehl P J, Chand R, et al. Nasal deposition of HFA-beclomethasone, aqueous fluticasone propionate and aqueous mometasone furoate in allergic rhinitis patients[J]. J Aerosol Med Pulm Drug Deliv, 2015, 28(5):334-340. [28] Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02(a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system)fills the gaps[J]. Expert Opin Pharmacother, 2015, 16(6):913-928. [29] Cavet M E, Volhejn S, Harrington K L, et al. Anti-allergic effects of mapracorat, a novel selective glucocorticoid receptor agonist, in human conjunctival fibroblasts and epithelial cells[J]. Mol Vis, 2013, 19:1515-1525. [30] Faria R, Mckenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis[J]. Value Health, 2014, 17(8):772-782. |
| [1] | 李梦欣,徐慧,张晓玲,薛晴,纪霜钰,李莹莹,崔丽梅,郭兆剑,宋西成,孙岩,陈良. 糖皮质激素通过下调水通道蛋白2缓解精氨酸加压素诱导的膜迷路积水[J]. 山东大学耳鼻喉眼学报, 2026, 40(3): 1-6. |
| [2] | 吕倩,唐源,顾子君,施赛磊,刘萍,万文锦. 变应性鼻炎患者疾病获益感现状及影响因素分析[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 21-28. |
| [3] | 顾敏,陆美萍. 纳米药物输送系统在变应性鼻炎过敏原免疫治疗中的应用进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 106-111. |
| [4] | 段思妤,薛金梅. 组蛋白去乙酰化酶2在慢性气道炎症性疾病糖皮质激素抵抗中的研究进展[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 120-126. |
| [5] | 秦娜娜,李玉芬,孙雨浩,魏健,李钦. 基于TGF-β1/Smad信号通路探讨白细胞介素13受体α2对变应性鼻炎大鼠鼻黏膜组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 71-77. |
| [6] | 熊琴, 张砚, 乌日娜, 李锋, 唐力行. 鼻用糖皮质激素在儿童中的应用[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 160-167. |
| [7] | 许雪萌,樊磊,喻望博,蒋芝月,潘晨,黄泳芹. 奥马珠单抗联合特异性免疫治疗变应性鼻炎疗效的Meta分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 26-33. |
| [8] | 刘怡君,谷悦,官大宇,杨玉成,沈暘. 翼管神经切断术在难治性变应性鼻炎中远期临床疗效和安全性[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 42-48. |
| [9] | 张婷,王美兰,高映勤. 白细胞介素35在变应性鼻炎中的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 139-147. |
| [10] | 张竹萍,彭孜灿,肖振龙,李程,喻迪,王兴龙,陈伟,郭蓓. 新型鼻分泌物嗜酸粒细胞阳离子蛋白-髓过氧化物酶试纸在变应性鼻炎中的应用价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(3): 129-134. |
| [11] | 曹正勇,李小波. 慢性鼻-鼻窦炎合并哮喘术后短程局部使用糖皮质激素辅助治疗的安全性和有效性[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 43-50. |
| [12] | 刘畅,杨景朴,高雨,王文佳. 长春地区儿童变应性鼻炎变应原检测结果分析[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 51-58. |
| [13] | 周荷青,申琪. 中医药治疗变应性鼻炎疗效的生物标志物研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(2): 168-176. |
| [14] | 王曼娴,郑泉,杨亮. 细菌裂解物治疗变应性鼻炎的研究进展[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 141-145. |
| [15] | 刘畅,方宏艳,刘敩,富东娜,王贺,王晶,杨景朴. 长春地区秋季变应性鼻炎蒿属花粉致敏特征分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(5): 13-19. |
|
||